CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Business sectors
- biotechnology industry [1]
- Company / filing name
- CRISPR Therapeutics AG [2]
- Headquarters location
- Zug [1]
- Founded
- 2013 [1]
- Legal form
- Aktiengesellschaft [1]
- Founders
- Emmanuelle Charpentier [1]
- Official website
- www.crisprtx.com ↗ [1]
- ISIN (reported securities)
- CH0334081137 [1]
- CIK
- 1674416 [2]
- Country in background record
- Switzerland [1]
- Symbols / exchanges
- CRSP (Nasdaq) [2]
Company positioning and business
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023. [3]
Background text: Wikipedia contributors, CRISPR Therapeutics. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
Listed securities: CRSP (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [2]
History and key events
Founding / inception date recorded in Wikidata. [1]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [2]
Related entities and concepts
Frequently asked questions
When was CRISPR Therapeutics AG founded?
Founded: 2013. The linked source provides the background record. [1]
Where is the headquarters of CRISPR Therapeutics AG?
Headquarters location: Zug. The linked source provides the background record. [1]
Which business sectors are recorded for CRISPR Therapeutics AG?
Business sectors: biotechnology industry. The linked source provides the background record. [1]
Sources and review dates
- Wikidata — company background record (CC0) ↗
- Company identity and profile data ↗
- Wikipedia contributors — CRISPR Therapeutics (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.